Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Marco Palmas"'
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 5, Pp 265-265 (2024)
Externí odkaz:
https://doaj.org/article/5c60b2608e614b2f9424ddd0f7d6f2f2
Autor:
Massimiliano Baleani, Paolo Erani, Manon Blaise, Roberta Fognani, Marco Palmas, Marco Manfrini
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
An intercalary segmental allograft is an option for limb salvage in bone tumours. Stable and congruent intercalary reconstructions are a prerequisite for achieving host-graft union. However, a too rigid fixation could increase the risk of late compli
Externí odkaz:
https://doaj.org/article/f834621ff65c47dd86030021432df31a
Publikováno v:
Geosciences, Vol 12, Iss 4, p 163 (2022)
Understanding the dynamics of mild explosive activity is a fundamental tool for hazard assessment at open conduit volcanoes. This is a particularly critical task for Etna volcano. Etna is in fact characterized by frequent, mild explosive activity, pu
Externí odkaz:
https://doaj.org/article/5b5cf9d665a04b058121590e5d407747
Autor:
Paolo Spinnato, Marco Colangeli, Amandine Crombé, Giulia Scalas, Marco Palmas, Tommaso Frisoni, Costantino Errani, Daniele Mercatelli, Laura Saenz Mesen, Laura Campanacci, Davide Maria Donati, Marco Manfrini
Publikováno v:
Surgical oncology. 45
Vascularized fibular autografts (VFA) are used in the oncologic skeletal reconstructions of long bones, alone or combined with massive bone allografts (MBA). Data regarding the role of imaging in assessing these complex skeletal reconstructions are l
Publikováno v:
Supportive Care in Cancer
Purpose Patients receiving platinum-based chemotherapy are at high risk of chemotherapy-induced nausea and vomiting (CINV), a distressing side effect of treatment. This post-hoc subgroup analysis of two pivotal trials evaluated the efficacy of NEPA i
Autor:
Marco Palmas, Matti Aapro, Giada Rizzi, Paul J. Hesketh, Richard J. Gralla, Karin Jordan, Giorgia Rossi
Publikováno v:
The Oncologist. 21:494-502
Background. Standard prophylaxis for chemotherapy-induced nausea and vomiting (CINV) with highly emetogenic and anthracycline-cyclophosphamide-based chemotherapy includes a 5-hydroxytryptamine-3 receptor antagonist, a neurokinin-1 receptor antagonist
Autor:
Paul J. Hesketh, Giada Rizzi, Marco Palmas, Richard J. Gralla, A. Lisyanskaya, G. Rossi, Anna Alyasova, Igor Bondarenko
Publikováno v:
Annals of Oncology
This study was designed to determine the appropriate clinical dose of netupitant (NETU), a new NK1 receptor antagonist (RA), to combine with the 5-HT3 RA, palonosetron (PALO) in a fixed-dose antiemetic combination (NEPA). All NEPA doses provided supe
Autor:
Matti Aapro, Giada Rizzi, Richard J. Gralla, Alla S. Lisyanskaya, Snežana M. Bošnjak, Karin Jordan, Giorgia Rossi, Anna V. Alyasova, Marco Palmas, Paul J. Hesketh
Publikováno v:
Journal of geriatric oncology. 8(1)
OBJECTIVES Prevention of chemotherapy-induced nausea and vomiting is critical in older patients with cancer. NEPA is an oral fixed combination of netupitant 300mg, a new NK1 receptor antagonist (RA), and palonosetron 0.5mg, a pharmacologically distin
Autor:
Maria Elisa Borroni, Hope S. Rugo, Marco Palmas, Meinolf Karthaus, K. Jordan, G. Rossi, Matti Aapro, Giada Rizzi, Richard J. Gralla, Lee S. Schwartzberg
Publikováno v:
Annals of Oncology. 25:iv518
Aim: As emesis is more difficult to suppress once it occurs, preventing chemotherapy-induced nausea and vomiting from the initial cycle through repeated cycles is essential for an optimal patient-centered approach to cancer management. NEPA is a nove
Autor:
Matti Aapro, Hope S. Rugo, Giada Rizzi, Maria Elisa Borroni, Lee S. Schwartzberg, Giorgia Rossi, Meinolf Karthaus, Marco Palmas
Publikováno v:
Journal of Clinical Oncology. 32:9502-9502
9502 Background: Antiemetic guidelines recommend co-administration of targeted prophylactic medications aimed at inhibiting several molecular pathways involved in emesis. NEPA is a novel, fixed-dos...